MBX Biosciences (MBX) announced the appointment of Karen Basbaum, MBA, as Chief Business Officer, CBO. Prior to joining MBX Biosciences, Basbaum served as Senior Vice President of Business Development at Poseida Therapeutics
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- MBX Biosciences Advances Canvuparatide After Phase 2 FDA Meeting
- MBX Biosciences ‘on track’ to initiate Phase 3 in Q3 following EOP 2 meeting
- MBX Biosciences Announces CFO Transition and Interim Appointment
- MBX Biosciences Raises $87 Million in ATM Offering
- MBX Biosciences initiated with an Overweight at Barclays